SAN FRANCISCO, Jan. 19, 2022 /PRNewswire/ -- Altos Labs™ (Altos™) launched today as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos' mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission.The Altos executive team will be composed of Hal Barron, MD (incoming CEO), Rick Klausner, MD (Chief…
WILMINGTON, Mass. & BOSTON--(BUSINESS WIRE)--Jan. 19, 2022-- Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development process, today announced the formation of a multiyear strategic partnership. This agreement will combine Valo’s Opal Computational Platform with Charles River’s drug discovery and development capabilities to offer a new transformative, AI-enabled drug discovery and development platform.
This…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP
First patient dosed in potential game-changing diabetes combination therapy
Cambridge, UK, 20 January 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has commenced the US Phase I clinical trial of Arecor’s lead product, AT247, an ultra-rapid insulin to be delivered by continuous subcutaneous infusion via insulin pump over a period of…
Designed to support PhoreMost’s phenotypic screening requirements and expertise, the new bespoke 14,900 sq ft state-of-the-art facility is split equally between office and laboratory space, with an additional 4,000 sq ft of warehouse storage. The space, within The Works, Unity Campus’ latest combined office and R&D building, enables the Company to add in-house flow cytometry and imaging capabilities. Nearly doubling the size of its previous facilities, the relocation accommodates PhoreMost’s accelerated expansion and ongoing recruitment efforts within one location, including the recent…
At a glance:
Virtual / fictional trade marks are, for example product or company names that only exist in a film or a computer game
Because of the popularity of the story or the medium in which the brands/products are featured, there is a desire to take advantage of the recognition and virtual reputation on the market
Under current laws rights holders often have to rely on copyright or forms of IP other than trade marks, as use of a brand name in virtual content or in the context of a made-up world does not necessarily provide protection in respect of physical goods
The legal landscape may…
We would like to invite you to participate in the SLAS Mentor Match program. SLAS is committed to transforming life sciences through research. We are an international professional society of academic, industry and government researchers as well as developers and providers of laboratory automation tools. The SLAS mentor program was developed to encourage experienced professionals (mentors) in our diverse community to pass on their knowledge and experience to young professionals (mentees). Pairs will be connected online via the Mentor Match portal and are matched by industry, career…
The agreement will facilitate understanding of complex relationships between microbiome, food and other factors, including potential causes of health and disease
Eagle Genomics, the Deep Tech software business pioneering the application of network science to biology, and the Quadram Institute, a world-leading institute creating new interfaces between food science, gut biology, and human health, are pleased to announce a new partnership committed to promoting the understanding of microbiome science. Building on the agreement announced in September 2021 with the Earlham Institute, a Norwich-…
Shenzhen, China and Cambridge, UK, 11 January, 2022: NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in China, and PhoreMost Limited (PhoreMost), the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, today announced an oncology drug discovery research collaboration.
As part of the collaboration, PhoreMost's SITESEEKER® phenotypic screening platform and NeoCura's full-process RNA drug design platform will be used to investigate the cellular delivery and efficacy of encoded targeted peptides. In…
Cambridge, UK - 12 January 2022 – Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator empowering life science researchers with high-quality biological reagents and tools critical to research, drug discovery and diagnostics, today received the Employees’ Choice Award 2022 recognizing Abcam in Glassdoor’s Best Places to Work in the UK. Abcam is the first biotech company to be ranked in the top five for two years in a row (1).
As the worldwide leader on insights about jobs and companies, Glassdoor celebrates, each year, outstanding employers throughout the world. Solely based on employees…
12th January 2022 (Rotterdam/Cambridge) – F.INSTITUTE, a Dutch full-service finance company for Life Sciences, Clean and Deep Tech companies, has expanded its portfolio with the launch of three new products: the Incubator, Seed and Series packages. The company has also expanded its CFO Services to include Partnering and M&A Services, and Fundraising Services. These products emphasize F.INSTITUTE’s ambition to become the European one-stop market leader for financial services for start-ups and scale-ups. F.INSTITUTE now offers specific financial packages for a fixed monthly fee to a…